These findings not only unravel a novel menin/JunD/Pbk axis for regulating compensatory proliferation of beta cells, but also highlight the menin/JunD/Pbk axis as a novel target for developing more effective therapy for T2D with potential long lasting effects. This evidence concerns the gene MEN1 and type 2 diabetes mellitus.